Inflation, competitive dynamics, and economic sustainability in the Spanish pharmaceutical sector
Journal of Pharmaceutical Health Services Research · 01.07.2026 · 17 (3)
DOI: 10.1093/jphsr/rmag014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Health Services Research, online erschienen am 01.07.2026. Verfasst von Fernando Abdalla Pereira und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Innovative Medicine.
Abstract (Originalsprache)
Objective
Spain’s pharmaceutical industry has faced inflation within a closely regulated pricing system. The objective of this study was to quantify the resulting economic pressure at sector level and for three medicines that exemplify different market situations.
Methods
Covering a 10-year period analysis, the study followed a four-stage framework. First, a narrative review described how inflation, competition, and regulation shape pharmaceutical pricing. Second, three medicines—ustekinumab, nivolumab, and daratumumab—were used to reflect the additional economic impact of distinct competitive mechanisms, including biosimilar entry, therapeutic competition within patented markets, and multi-indication repricing. Third, macro-economic series (consumer-price indexes, wages, electricity, and fuel indices), industry accounts, and price–volume data were consolidated with national tender records. Finally, cost–turnover indices and unit-level price models quantified resulting economic impacts. Key findings Cumulative excess sector costs attributable to inflation totalled €6.5 billion. Purchases of goods and services and staff each accounted for €3.1 billion, while energy added €0.3 billion. At medicine level, the combined economic impact of unadjusted list prices, inflation-driven production costs, and reimbursed-price reductions amounted to €494 million for ustekinumab, reflecting approaching biosimilar competition; €498 million for nivolumab, associated with successive indication-based repricing within a value-alignment framework; and €580 million for daratumumab, in the context of intense competition.
Conclusions
Inflation, regulated pricing mechanisms, and competitive repricing coincided with a measurable divergence between cost evolution and revenues. Transparent and publicly available metrics would provide a reliable baseline for monitoring Spain’s pharmaceutical adaptability within an evolving macro-economic conditions landscape.
Förderung
- Johnson & Johnson Innovative Medicine
Zitieren
APA
Pereira, F. A., Villaseca, J., Parra, R., Beas, D., Ruiz, N., Dominguez, T., & Hidalgo-Vega, Á. (2026). Inflation, competitive dynamics, and economic sustainability in the Spanish pharmaceutical sector. Journal of Pharmaceutical Health Services Research, 17(3). https://doi.org/10.1093/jphsr/rmag014
Vancouver
Pereira FA, Villaseca J, Parra R, Beas D, Ruiz N, Dominguez T, et al. Inflation, competitive dynamics, and economic sustainability in the Spanish pharmaceutical sector. Journal of Pharmaceutical Health Services Research. 2026;17(3). doi:10.1093/jphsr/rmag014
BibTeX
@article{Pereira2026,
author = {Pereira, Fernando Abdalla and Villaseca, Javier and Parra, Rafael and Beas, David and Ruiz, Nuria and Dominguez, Teresa and Hidalgo-Vega, Álvaro},
title = {Inflation, competitive dynamics, and economic sustainability in the Spanish pharmaceutical sector},
journal = {Journal of Pharmaceutical Health Services Research},
year = {2026},
volume = {17},
number = {3},
doi = {10.1093/jphsr/rmag014}
}
EUVIMED